Literature DB >> 14671046

Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Hugh C Rayner1, Ronald L Pisoni, Juergen Bommer, Bernard Canaud, Erwin Hecking, Francesco Locatelli, Luis Piera, Jennifer L Bragg-Gresham, Harold I Feldman, David A Goodkin, Brenda Gillespie, Robert A Wolfe, Philip J Held, Friedrich K Port.   

Abstract

BACKGROUND: Mortality and hospitalization rates are reported for nationally representative random samples of haemodialysis patients treated at randomly selected dialysis facilities in five European countries participating in the Dialysis Outcomes and Practice Pattern Study (DOPPS) (France, Germany, Italy, Spain and the UK).
RESULTS: In the UK, 28.1% of haemodialysis patients received prior peritoneal dialysis treatment compared with 4.2-8.3% in other countries. Kidney transplantation rates ranged from 3.3 (per 100 patient years) in Italy to 11.6 in Spain. The relative risk (RR) of mortality, adjusted for age, sex and diabetes status was significantly higher in the UK (RR = 1.39, P = 0.02) compared with Italy (reference) and increased in association with age (RR = 1.60 for every 10 years older, P <0.001), diabetes as cause of end-stage renal disease (ESRD) (RR = 1.55, P < 0.001), male patients <65 years (RR = 1.29, P = 0.02) and peritoneal dialysis in the 12 months prior to starting haemodialysis (RR = 1.72, P = 0.06). Hospitalization for cardiovascular disease was highest in France and Germany (0.40 and 0.43 hospitalizations per patient year, respectively) and lowest in the UK (0.19), although cardiovascular comorbidity was similar in the UK and France. Hospitalization rates for vascular access-related infection ranged from 0.01 hospitalizations per patient year in Italy to 0.08 in the UK, consistent with the higher dialysis catheter use in the UK (25%) vs Italy (5%). Hospitalization risk was significantly higher in France than in other Euro-DOPPS countries and was significantly (P < 0.05) associated with prior peritoneal dialysis therapy, peripheral vascular disease, gastrointestinal bleeding in the prior 12 months, diabetes, cancer, cardiac disease, psychiatric disease and recent onset of ESRD (within 30 days of study entry).
CONCLUSIONS: The large differences in haemodialysis practice and outcomes in the Euro-DOPPS countries suggest opportunities for improvement in patient care.

Entities:  

Mesh:

Year:  2004        PMID: 14671046     DOI: 10.1093/ndt/gfg483

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  67 in total

Review 1.  Future research directions to improve fistula maturation and reduce access failure.

Authors:  Haidi Hu; Sandeep Patel; Jesse J Hanisch; Jeans M Santana; Takuya Hashimoto; Hualong Bai; Tambudzai Kudze; Trenton R Foster; Jianming Guo; Bogdan Yatsula; Janice Tsui; Alan Dardik
Journal:  Semin Vasc Surg       Date:  2016-08-26       Impact factor: 1.000

2.  Statin therapy is not associated with improved vascular access outcomes.

Authors:  Roberto Pisoni; Jill Barker-Finkel; Michael Allo
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-27       Impact factor: 8.237

Review 3.  End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF).

Authors:  Avi Dor; Mark V Pauly; Margaret A Eichleay; Philip J Held
Journal:  Int J Health Care Finance Econ       Date:  2007-09

4.  International Study of Health Care Organization and Financing of renal services in England and Wales.

Authors:  Tricia Nicholson; Paul Roderick
Journal:  Int J Health Care Finance Econ       Date:  2007-12

5.  International study of health care organization and financing: development of renal replacement therapy in Germany.

Authors:  Werner Kleophas; Helmut Reichel
Journal:  Int J Health Care Finance Econ       Date:  2007-09

6.  Malnutrition in pre-dialysis chronic kidney disease patients in a teaching hospital in Southern Nigeria.

Authors:  Adejumo Oluseyi; Okaka Enajite
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

7.  Outcomes of Infection-Related Hospitalization according to Dialysis Modality.

Authors:  Louis-Philippe Laurin; Hind Harrak; Naoual Elftouh; Denis Ouimet; Michel Vallée; Jean-Philippe Lafrance
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-27       Impact factor: 8.237

8.  Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis.

Authors:  Jean-Philippe Lafrance; Elham Rahme; Sameena Iqbal; Naoual Elftouh; Michel Vallée; Louis-Philippe Laurin; Denis Ouimet
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 8.237

Review 9.  Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin Receptor Activator).

Authors:  Usha Panchapakesan; Siska Sumual; Carol Pollock
Journal:  Int J Nanomedicine       Date:  2007

10.  Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER--a multicentre, prospective, observational cohort study.

Authors:  Rafael Pérez-García; Alejandro Martín-Malo; Joan Fort; Xavier Cuevas; Fina Lladós; Javier Lozano; Fernando García
Journal:  Nephrol Dial Transplant       Date:  2008-11-21       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.